Novavax
phone-call sandwich
Novavax

Novavax

The third phase of trials of this peptide vaccine from United States-based Novavax began in September 2020. In total, more than 45,000 volunteers will take part in the vaccine study, to be conducted in the UK and the USA. After the drug is approved, deliveries are planned to the United States, United Kingdom and Australia.
Novavax

Novavax

The third phase of trials of this peptide vaccine from United States-based Novavax began in September 2020. In total, more than 45,000 volunteers will take part in the vaccine study, to be conducted in the UK and the USA. After the drug is approved, deliveries are planned to the United States, United Kingdom and Australia. The vaccine includes a viral spike protein, NVX-CoV2373, produced in moth cells infected with a baculovirus (which cause illnesses in insects). Scientists included a gene from a whole coronavirus spike protein in this baculovirus, forcing the moth’s cells to serve as a factory to produce viral proteins. After this, proteins were assembled into nanoparticles with saponins extracted from soapberry trees used as an adjuvant.

Vaccine

NVX-CoV2373 (Novavax)

Developer

Novavax

Producer

Novavax

Status

In March 2020, Novavox announced a partnership with Emergent BioSolutions to conduct pre-clinical and early studies of its vaccine in humans. As part of the partnership, Emergent BioSolutions will begin mass production of the vaccine at its facility in Baltimore.
The first evaluations of human safety for NVX-CoV2373 began in May 2020 in Australia.

Key information

What’s in the vaccine?

NVX-CoV2373 is a vaccine against COVID-19 based on protein sub-particles containing SARS-CoV-2 spike proteins.



Vaccines developed and used in Russia